PS
PeptideScholar

Content reviewed by clinical research staff

Last reviewed: March 2026Sources: PubMed, FDA, WADA Prohibited List

Evidence graded using the PeptideScholar A-D system

Survodutide

BHuman Studies

Dual GLP-1/Glucagon receptor agonist · 29 amino acids

Not FDA ApprovedPrescription Required

Survodutide is a dual GLP-1 and glucagon receptor agonist developed by Boehringer Ingelheim. In Phase 3 trials, it demonstrates significant weight loss and is also being investigated for metabolic dysfunction-associated steatohepatitis (MASH/NAFLD).

Mechanism of Action

Dual agonist targeting GLP-1 receptors (appetite suppression, insulin secretion) and glucagon receptors (increased energy expenditure, hepatic lipid metabolism). The glucagon component drives liver fat reduction, differentiating it from GLP-1-only agonists.

Benefits

  • Up to 19% weight loss in Phase 2 trials
  • Significant liver fat reduction for MASH
  • Dual mechanism targets both weight and liver disease
  • Once-weekly dosing
Not Medical Advice — Research-Reported Information Only

This content is for informational purposes only and does not constitute medical advice.

Survodutide — Dosing in Published Research

Reported Routes: Subcutaneous injection
Phase 3 trials testing multiple dose levels administered SC weekly. Trials ongoing for both obesity (SYNCHRONIZE) and MASH indications.

The dosing information above is sourced from published research literature and clinical trials. These are not recommendations. Individual responses vary. Always consult a healthcare provider before considering any peptide-based therapy.

Side Effects

  • Nausea and vomiting
  • Diarrhea
  • Decreased appetite
  • Injection site reactions
  • Long-term safety data still being collected

Considering Peptide Research?

Survodutide is not FDA-approved. Always consult a licensed healthcare provider before considering any peptide.

Learn About Finding a Provider
Always Consult a Professional

Research & Evidence

RCTThe Lancet, 2024

Survodutide for the Treatment of Obesity

Survodutide produced up to 19% weight loss at 46 weeks with significant improvements in cardiometabolic markers

PMID: 37840091

Compare Survodutide With

Survodutide vs Tirzepatide
Survodutide vs Retatrutide

References

  1. 1. Survodutide for the Treatment of Obesity. The Lancet, 2024. “Survodutide produced up to 19% weight loss at 46 weeks with significant improvements in cardiometabolic markers” [PMID: 37840091]

Recommended Resources

The Peptide Protocols Handbook

Evidence-based reference guide covering mechanisms, research, and clinical applications.

View on Amazon

Third-Party Peptide Testing

Independent lab analysis to verify peptide purity and authenticity.

Learn More

Links may be affiliate links. See our disclosure.

Survodutide FAQ

Medical Disclaimer

This content is for informational and educational purposes only and does not constitute medical advice, diagnosis, or treatment recommendations.

Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment. Do not disregard professional medical advice based on information found on this site.

No claims of therapeutic efficacy are made for substances that are not FDA-approved for the discussed indications. Research citations reflect published findings and do not imply endorsement.

Get Peptide Research Updates

Weekly evidence summaries and regulatory alerts.

No spam. Unsubscribe anytime.